Healthcare

In DDW and ELRIG UK’s Drug Discovery 2021 supplement, CEO and Founder of Egality Health, Annette Crosse, offers insight into the importance of diversity in clinical trials and of overcoming limitations in healthcare research to re-imagine a system which provides safe, effective and innovative therapies for the entire population.  Annette Crosse describes Egality Health as a start-up […]

Novartis has announced that eligible patients in England and Wales will soon have routine access to Adakveo (crizanlizumab) under a Managed Access Agreement (MAA), which the company says not only helps with sickle cell disease (SCD), but also demonstrates a commitment to supporting health equity for a community that has been historically underserved, without any new treatment options for […]

Artificial Intelligence (AI) is the simulation of human intelligence processes by machines, particularly computer systems, and finds itself at a climactic moment for its use within the drug discovery industry, especially as the world emerges from the Covid-19 pandemic.   “Artificial intelligence and machine learning continue to play important roles in drug discovery”, said Rupert Vessey, […]

According to Thermo Fisher Scientific, lab managers, technology leaders and principal scientists in pharmaceutical, food and environmental laboratories can use its new mass specrometry (MS) portfolio and chromatography solutions to accelerate throughput and improve sensitivity to meet rapidly changing regulatory requirements and the fast responses needed to tackle emerging human and environmental health risks.  The Thermo Scientific […]

Following a thorough review of evidence carried out by the Medicines and Healthcare products Regulatory Agency (MHRA) and recommendation by the Commission on Human Medicines (CHM), the UK government’s independent expert scientific advisory body, the MHRA has approved Ronapreve as the first monoclonal antibody combination product indicated for use in the prevention and treatment of acute Covid-19 […]

At an update to investors, GlaxoSmithKline (GSK) provided details of its strategy, outlook for growth and plans to create shareholder value, following the planned demerger in mid-2022 of its Consumer Healthcare business. An equity research expert suggests that while targets are friendly, investors will not get a completely clean break from the new consumer business. […]